Clinical trial · Observational
Geriatric Assessments in Senior Adults With Multiple Myeloma
Pilot Study of Geriatric Assessments in Senior Adults With Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the prevalence of geriatric syndromes in older adults with multiple myeloma, examine relationships between baseline geriatrics syndromes and initial treatment selection, and examine risk of functional decline. Relationship between baseline geriatric questionnaires and initial treatment selection in older adults with newly diagnosed multiple myeloma. Feasibility of subjects completing the CARG geriatric assessments at baseline, 3 months and 6 months. Comorbidities or dependence in IADLs at baseline predict decline in functional status at 6 months of follow-up in older adults with newly diagnosed multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Questionnaires
- description
- No treatment
Primary outcomes (1)
- measure
- The relationship between initial treatment recommendation and baseline questionnaires assessment
- timeFrame
- At baseline visit
- description
- The physician caring for the patient will be asked to identify his/her initial treatment recommendations. This includes whether the patient is, in his/her assessment, a candidate for high dose therapy and autologous stem cell transplantation. It will also include whether a 2-drug or 3-drug regimen is recommended initially.
Secondary outcomes (2)
- measure
- Changes in questionnaires from baseline to 6 months
- timeFrame
- Through 6 months of follow-up
- description
- Logistic regression analyses, adjusted odds ratios (ORs) based on model will be given with 95% CIs. All analyses will use two-tailed significance levels of 0.05 and will be conducted with statistical software SAS 9.2. Geriatric assessment variables will be analyzed as continuous or ordinal variables as indicated. Candidate variables will include: demographic data (including age, gender, race), disease data (stage, cytogenetic abnormalities), or geriatric assessment variables (comorbidity, functional status, physical function, psychological state, nutrition, social support and social activity). Analyses will be performed for the outcomes of treatment selection (transplant vs non-transplant) and increased dependence in IADLs
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patient must have a diagnosis of multiple myeloma by IMWF criteria: diagnosis must have occurred within 3 months of study enrollment. * Patient must be ≥ 65 years of age. * Patient's life expectancy must be ≥ 6 months. * Patient must be willing to complete follow-up assessments. * Patient must be able to understand and willing to sign a written informed consent document. Exclusion Criteria: * Patient must not have a diagnosis of smoldering myeloma. * Patient must not have concomitant amyloidosis.
References
Publications (0)
Data not yet available